The curative effect of HAIC combined with PD1 inhibitors and anti-angiogenesis therapy for advance hepatocellular carcinoma
10.3969/j.issn.1008-794X.2025.07.007
- VernacularTitle:HAIC联合PD1抑制剂及抗血管生成药物致晚期肝癌完全缓解病例分析
- Author:
Shitao LU
1
;
Yapan GUO
;
Wencong FENG
;
Jun YANG
;
Yu YIN
;
Zhi LI
Author Information
1. 215000 江苏苏州 苏州大学附属第一医院介入科
- Keywords:
hepatocellular carcinoma;
hepatic arterial infusion chemotherapy;
PD-1 inhibitor;
anti-angiogenesis therapy;
complete Remission
- From:
Journal of Interventional Radiology
2025;34(7):724-729
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the curative effect of hepatic arterial infusion chemotherapy(HAIC)combined with programmed death receptor-1(PD-1)inhibitors and anti-angiogenesis therapy for BCLC stage C hepatocellular carcinoma(HCC).Methods The patients with HCC of BCLC stage C,who received HAIC combined with PD-1 inhibitors and anti-angiogenesis therapy at the First Affiliated Hospital of Soochow University of China from January 2021 to December 2023,were collected for this study.The time from the start of treatment to complete remission(CR)of disease,the dynamic changes in alpha-fetoprotein(AFP)levels and the recurrence during follow-up period were analyzed.The relevant literature of the above triple regimen for HCC was searched from PubMed database and its curative effect was analyzed.Results Of the 214 HCC patients treated with triple therapy regimen,9(4.2％)achieved CR.The time from the start of treatment to CR was 2-10 months.The patients were followed up for 5-20 months.The time of AFP level returning to normal value was from 79 to 259 days.One patient developed recurrence 10 months after CR,and the other 8 patients maintained the CR status.A total of 12 articles were retrieved,the reported CR rates ranged from 0 to 16.5％.Conclusion A CR can be achieved in a few patients with advanced HCC treated with HAIC combined with PD-1 inhibitors and anti-angiogenesis therapy.
